Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 90 P657 | DOI: 10.1530/endoabs.90.P657

1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Endocrinology and Diabetology Unit, Milan, Italy; 2Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain; 3University of Cordoba, Department of Cell Biology, Physiology and Immunology, Cordoba, Spain; 4Reina Sofia University Hospital, Cordoba, Spain; 5University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy; 6University Medical Center Hamburg-Eppendorf, I. Medical Department, Hamburg, Germany; 7CIBER Physiopathology of Obesity and Nutrition, Cordoba, Spain


Neuroendocrine tumors (NETs) and carcinomas (NECs) are a heterogeneous group of malignances whose incidence is increasing worldwide. First-line approach is represented by surgery, whereas an effective pharmacological treatment for disseminated and relapsing disease is still needed. Somatostatin (SS) receptors (SSTs) constitute the main suitable pharmacological targets for NETs therapy with SS analogs (SSAs). Nevertheless, a large proportion of NETs and most NECs, are unresponsive or resistant to SSAs and the causes that underline resistance still remain poorly understood, highlighting the need of alternative strategies. Recently, the neuropeptide cortistatin (CST), that shares with SS actions and affinity to SSTs, emerged as an anti-inflammatory player, showing potential antitumoral behavior. The aim of this study was to characterize the SS and CST system in different NETs and NECs cell models. More precisely, the effects of SS/CST and selected analogs were tested on cell proliferation and apoptosis on classical (BON-1, QGP-1) and novel Pan-NETs (NT-18P, NT-18LM) and Pan-NEC (NT-38) cell lines. Our data shows that SSAs exerted limited actions on cell proliferation in novel cell lines. On the other hand, CST treatment induced dose and time-dependent effects: while it caused limited actions in BON-1 and QGP-1 cells, it exerted significative inhibition of cell proliferation, and induced apoptosis in NT-18P, NT-18LM, and NT-38 cells. Interestingly, each model used displayed a unique SSTs expression profile, which may underlie their different response to treatments. Our study provides an initial characterization of novel Pan-NETs and Pan-NECs cell models, more accurately resembling human tumors behavior, in response to various drugs, paving the way for novel original avenues to explore new therapeutical approaches for NETs/NECs treatment.

Volume 90

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.